JP2020518083A - 免疫原性がん特異的エピトープのためのランク付けシステム - Google Patents
免疫原性がん特異的エピトープのためのランク付けシステム Download PDFInfo
- Publication number
- JP2020518083A JP2020518083A JP2020502531A JP2020502531A JP2020518083A JP 2020518083 A JP2020518083 A JP 2020518083A JP 2020502531 A JP2020502531 A JP 2020502531A JP 2020502531 A JP2020502531 A JP 2020502531A JP 2020518083 A JP2020518083 A JP 2020518083A
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- epitope
- mhc class
- factors
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000002163 immunogen Effects 0.000 title claims abstract description 37
- 206010028980 Neoplasm Diseases 0.000 title abstract description 60
- 201000011510 cancer Diseases 0.000 title abstract description 18
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 324
- 230000028993 immune response Effects 0.000 claims abstract description 97
- 108091054437 MHC class I family Proteins 0.000 claims abstract description 93
- 102000043129 MHC class I family Human genes 0.000 claims abstract description 93
- 102000043131 MHC class II family Human genes 0.000 claims abstract description 72
- 108091054438 MHC class II family Proteins 0.000 claims abstract description 72
- 238000000034 method Methods 0.000 claims abstract description 68
- 230000035772 mutation Effects 0.000 claims abstract description 54
- 108700028369 Alleles Proteins 0.000 claims abstract description 50
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 18
- 201000010099 disease Diseases 0.000 claims abstract description 16
- 230000005867 T cell response Effects 0.000 claims abstract description 11
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims abstract description 10
- 210000002443 helper t lymphocyte Anatomy 0.000 claims abstract description 9
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 87
- 239000000427 antigen Substances 0.000 claims description 70
- 108091007433 antigens Proteins 0.000 claims description 70
- 102000036639 antigens Human genes 0.000 claims description 70
- 230000005847 immunogenicity Effects 0.000 claims description 54
- 108090000623 proteins and genes Proteins 0.000 claims description 45
- 102000004169 proteins and genes Human genes 0.000 claims description 28
- 230000014509 gene expression Effects 0.000 claims description 25
- 238000010801 machine learning Methods 0.000 claims description 22
- 230000036438 mutation frequency Effects 0.000 claims description 9
- 210000001744 T-lymphocyte Anatomy 0.000 abstract description 97
- 238000011282 treatment Methods 0.000 abstract description 11
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 57
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 57
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 56
- 238000012549 training Methods 0.000 description 48
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 43
- 239000000523 sample Substances 0.000 description 34
- 238000012360 testing method Methods 0.000 description 31
- 210000004027 cell Anatomy 0.000 description 24
- 238000007477 logistic regression Methods 0.000 description 20
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 18
- 230000030741 antigen processing and presentation Effects 0.000 description 17
- 230000004044 response Effects 0.000 description 17
- 150000001413 amino acids Chemical class 0.000 description 16
- 210000004881 tumor cell Anatomy 0.000 description 16
- 230000008569 process Effects 0.000 description 15
- 238000000585 Mann–Whitney U test Methods 0.000 description 12
- 210000002865 immune cell Anatomy 0.000 description 12
- 230000006044 T cell activation Effects 0.000 description 10
- 238000002790 cross-validation Methods 0.000 description 10
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 9
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 9
- 238000004364 calculation method Methods 0.000 description 9
- 210000000612 antigen-presenting cell Anatomy 0.000 description 8
- 238000007481 next generation sequencing Methods 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000009169 immunotherapy Methods 0.000 description 7
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 5
- 238000001994 activation Methods 0.000 description 5
- 238000003776 cleavage reaction Methods 0.000 description 5
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 5
- 210000000987 immune system Anatomy 0.000 description 5
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 5
- 230000007017 scission Effects 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 229960005486 vaccine Drugs 0.000 description 5
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 description 4
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 238000009566 cancer vaccine Methods 0.000 description 4
- 229940022399 cancer vaccine Drugs 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000002864 sequence alignment Methods 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 3
- 108090000144 Human Proteins Proteins 0.000 description 3
- 102000003839 Human Proteins Human genes 0.000 description 3
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 3
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 3
- 108091008874 T cell receptors Proteins 0.000 description 3
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000005859 cell recognition Effects 0.000 description 3
- 230000033077 cellular process Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000005457 optimization Methods 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 206010069754 Acquired gene mutation Diseases 0.000 description 2
- 101100284398 Bos taurus BoLA-DQB gene Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 101001100327 Homo sapiens RNA-binding protein 45 Proteins 0.000 description 2
- 102100038823 RNA-binding protein 45 Human genes 0.000 description 2
- 230000006052 T cell proliferation Effects 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000002619 cancer immunotherapy Methods 0.000 description 2
- 238000001516 cell proliferation assay Methods 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- 230000005934 immune activation Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 230000002998 immunogenetic effect Effects 0.000 description 2
- 230000001024 immunotherapeutic effect Effects 0.000 description 2
- 238000011293 immunotherapeutic strategy Methods 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 230000037439 somatic mutation Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 229940021747 therapeutic vaccine Drugs 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 108091093088 Amplicon Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 230000004536 DNA copy number loss Effects 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 238000007476 Maximum Likelihood Methods 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 102100026450 POU domain, class 3, transcription factor 4 Human genes 0.000 description 1
- 101710133389 POU domain, class 3, transcription factor 4 Proteins 0.000 description 1
- 238000003559 RNA-seq method Methods 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000013528 artificial neural network Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000008711 chromosomal rearrangement Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 231100000221 frame shift mutation induction Toxicity 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000008004 immune attack Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011337 individualized treatment Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000007403 mPCR Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000012067 mathematical method Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 230000003094 perturbing effect Effects 0.000 description 1
- 229940021993 prophylactic vaccine Drugs 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000013077 scoring method Methods 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 230000037436 splice-site mutation Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000012706 support-vector machine Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 238000007482 whole exome sequencing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- G16B40/20—Supervised data analysis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Medical Informatics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Evolutionary Biology (AREA)
- Biotechnology (AREA)
- Theoretical Computer Science (AREA)
- Bioinformatics & Computational Biology (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Data Mining & Analysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Artificial Intelligence (AREA)
- Bioethics (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Databases & Information Systems (AREA)
- Evolutionary Computation (AREA)
Abstract
Description
Claims (24)
- 少なくとも1種の免疫原性変異ペプチドを選択するための方法であって、
(a)複数の変異配列を得ること、
(b)疾患関連変異に由来する少なくとも1つのエピトープを同定すること、
(c)前記少なくとも1つのエピトープの免疫原性に関連する複数の因子を取り込むこと、
(d)前記複数の因子を重み付けること、
(e)前記複数の因子の重みに基づいて前記少なくとも1つのエピトープに免疫原性スコアを割り当てること、
(f)前記少なくとも1つのエピトープをランク付けすること、及び
(g)工程(f)におけるランク付け結果に基づいて前記免疫原性変異ペプチドを選択すること、
を含み、
前記免疫原性変異ペプチドが、T細胞応答を引き起こし得る少なくとも1つのエピトープを含む、方法。 - 工程(c)〜工程(e)の内の1つが、機械学習モデルを利用して達成される、請求項1に記載の方法。
- 100個以下のエピトープが選択される、請求項1又は請求項2に記載の方法。
- 50個以下のエピトープが選択される、請求項3に記載の方法。
- 30個以下のエピトープが選択される、請求項4に記載の方法。
- 10個以下のエピトープが選択される、請求項5に記載の方法。
- 10個〜30個のエピトープが選択される、請求項5に記載の方法。
- 前記複数の因子が、MHCクラスI及びMHCクラスIIによる前記エピトープの提示を対象に含む、請求項1〜請求項7のいずれか一項に記載の方法。
- MHCクラスIを有する前記選択されたエピトープの結合親和性が、1500nM未満のIC50値である、請求項8に記載の方法。
- 前記複数の因子がMHCクラスI結合安定性を含む、請求項8又は請求項9に記載の方法。
- 前記複数の因子が、タンパク質存在量、遺伝子発現、又はそれらの組み合わせを含む、請求項8〜請求項10のいずれか一項に記載の方法。
- 前記複数の因子が、細胞傷害性T細胞において免疫応答を引き起こす前記エピトープの能力を対象に含む、請求項1〜請求項11のいずれか一項に記載の方法。
- 前記複数の因子が、ヘルパーT細胞における免疫応答を引き起こす前記エピトープの能力を対象に含む、請求項1〜請求項12のいずれか一項に記載の方法。
- 前記複数の因子が、自己ペプチドに対する前記エピトープの類似性を含む、請求項12又は請求項13に記載の方法。
- 前記複数の因子が、既知の抗原に対する前記エピトープの相同性を含む、請求項12〜請求項14のいずれか一項に記載の方法。
- 前記変異の変異頻度が少なくとも10%である、請求項1〜請求項15のいずれか一項に記載の方法。
- 前記変異の前記変異頻度が少なくとも30%である、請求項16に記載の方法。
- 前記変異が、2つ以上のコピーと共に存在する、請求項1〜請求項17のいずれか一項に記載の方法。
- 前記複数の因子の内の1つがヘテロ接合性の消失である、請求項1〜請求項18のいずれか一項に記載の方法。
- 前記複数の因子の内の1つがアレル本数である、請求項1〜請求項19のいずれか一項に記載の方法。
- 前記複数の因子の内の1つが、前記疾患関連変異のクローナリティである、請求項1〜請求項20のいずれか一項に記載の方法。
- 前記免疫原性スコアが、ペプチドレベルスコアを算出するために用いられ得る因子と、試料レベルスコアを算出するために用いられ得る因子と、を含む前記複数の因子が統合されてなる、請求項1〜請求項21のいずれか一項に記載の方法。
- 前記免疫原性スコアが、MHCクラスI及びMHCクラスIIによる前記エピトープの提示と、ヘルパーT細胞及び細胞傷害性T細胞の両方において免疫応答を引き起こす前記エピトープの能力と、前記疾患関連変異のクローナリティと、を含む複数の因子が統合されてなる、請求項1に記載の方法。
- 少なくとも1種の免疫原性変異ペプチドを選択するためのシステムであって、
コンピュータにより実行可能な手段である
(a)複数の変異配列を得ること、
(b)疾患関連変異に由来する少なくとも1つのエピトープを同定すること、
(c)前記少なくとも1つのエピトープの免疫原性に関連する複数の因子を取り込むこと、
(d)前記複数の因子を重み付けること、
(e)前記複数の因子の重みに基づいて前記少なくとも1つのエピトープに免疫原性スコアを割り当てること、
(f)前記少なくとも1つのエピトープをランク付けすること、及び
(g)工程(f)におけるランク付け結果に基づいて前記免疫原性変異ペプチドを選択すること
を記憶するハードウェアメモリを含み、
前記免疫原性変異ペプチドが、T細胞応答を引き起こし得る少なくとも1つのエピトープを含む、システム。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762479320P | 2017-03-31 | 2017-03-31 | |
US62/479,320 | 2017-03-31 | ||
PCT/US2018/025597 WO2018183980A2 (en) | 2017-03-31 | 2018-03-31 | Ranking system for immunogenic cancer-specific epitopes |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2020518083A true JP2020518083A (ja) | 2020-06-18 |
JP2020518083A5 JP2020518083A5 (ja) | 2020-07-30 |
JP7155470B2 JP7155470B2 (ja) | 2022-10-19 |
Family
ID=63676910
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020502531A Active JP7155470B2 (ja) | 2017-03-31 | 2018-03-31 | 免疫原性がん特異的エピトープのためのランク付けシステム |
Country Status (7)
Country | Link |
---|---|
US (1) | US11485784B2 (ja) |
EP (1) | EP3600340A4 (ja) |
JP (1) | JP7155470B2 (ja) |
CN (1) | CN110799196B (ja) |
SG (1) | SG11201907738UA (ja) |
TW (1) | TWI672503B (ja) |
WO (1) | WO2018183980A2 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2022518355A (ja) * | 2018-12-21 | 2022-03-15 | ビオンテック ユーエス インコーポレイテッド | Hlaクラスii特異的エピトープの予測およびcd4+ t細胞の特徴付けのための方法およびシステム |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2729116C2 (ru) * | 2015-12-16 | 2020-08-04 | Гритстоун Онколоджи, Инк. | Идентификация, производство и применение неоантигенов |
BR112019021782A2 (pt) * | 2017-04-19 | 2020-08-18 | Gritstone Oncology, Inc. | identificação, fabricação e uso de neoantígenos |
US11885815B2 (en) | 2017-11-22 | 2024-01-30 | Gritstone Bio, Inc. | Reducing junction epitope presentation for neoantigens |
BR112021005353A2 (pt) * | 2018-11-21 | 2021-06-15 | Nec Corporation | método e sistema de direcionamento de epitopos para imunoterapia baseada em neoantígeno |
EP3931834A1 (en) | 2019-02-28 | 2022-01-05 | Universiteit Antwerpen | Method for determining responsiveness to an epitope |
US20220208306A1 (en) * | 2019-04-30 | 2022-06-30 | Memorial Sloan Kettering Cancer Center | System and methods for identification of non-immunogenic epitopes and determining efficacy of epitopes in therapeutic regimens |
TWI832443B (zh) * | 2021-09-28 | 2024-02-11 | 香港商行動基因(智財)有限公司 | 甲基化生物標記選擇裝置及方法 |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005301523A (ja) * | 2004-04-08 | 2005-10-27 | Celestar Lexico-Sciences Inc | ワクチン候補部分配列予測装置、ワクチン候補部分配列予測方法、mhc結合部分配列予測装置、mhc結合部分配列予測方法、プログラムおよび記録媒体 |
JP2016506907A (ja) * | 2013-01-15 | 2016-03-07 | メモリアル スローン−ケタリング キャンサー センター | 免疫原性wt−1ペプチドおよびその使用法 |
WO2016040682A1 (en) * | 2014-09-10 | 2016-03-17 | Genentech, Inc. | Immunogenic mutant peptide screening platform |
US20160101170A1 (en) * | 2013-04-07 | 2016-04-14 | The Broad Institute Inc. | Compositions and methods for personalized neoplasia vaccines |
WO2016128376A1 (en) * | 2015-02-12 | 2016-08-18 | Biontech Ag | Predicting t cell epitopes useful for vaccination |
WO2016172722A1 (en) * | 2015-04-23 | 2016-10-27 | Nantomics, Llc | Cancer neoepitopes |
WO2016174085A1 (en) * | 2015-04-27 | 2016-11-03 | Cancer Research Technology Limited | Method for treating cancer |
WO2017011660A1 (en) * | 2015-07-14 | 2017-01-19 | Personal Genome Diagnostics, Inc. | Neoantigen analysis |
WO2017042394A1 (en) * | 2015-09-10 | 2017-03-16 | Cancer Research Technology Limited | "immune checkpoint intervention" in cancer |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013040142A2 (en) * | 2011-09-16 | 2013-03-21 | Iogenetics, Llc | Bioinformatic processes for determination of peptide binding |
CN107704727B (zh) * | 2017-11-03 | 2020-01-31 | 杭州风起智能科技有限公司 | 基于肿瘤新抗原特征值的新抗原活性预测和排序方法 |
-
2018
- 2018-03-31 JP JP2020502531A patent/JP7155470B2/ja active Active
- 2018-03-31 US US16/497,442 patent/US11485784B2/en active Active
- 2018-03-31 WO PCT/US2018/025597 patent/WO2018183980A2/en active Application Filing
- 2018-03-31 EP EP18776882.5A patent/EP3600340A4/en active Pending
- 2018-03-31 TW TW107111453A patent/TWI672503B/zh active
- 2018-03-31 SG SG11201907738UA patent/SG11201907738UA/en unknown
- 2018-03-31 CN CN201880019637.1A patent/CN110799196B/zh active Active
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005301523A (ja) * | 2004-04-08 | 2005-10-27 | Celestar Lexico-Sciences Inc | ワクチン候補部分配列予測装置、ワクチン候補部分配列予測方法、mhc結合部分配列予測装置、mhc結合部分配列予測方法、プログラムおよび記録媒体 |
JP2016506907A (ja) * | 2013-01-15 | 2016-03-07 | メモリアル スローン−ケタリング キャンサー センター | 免疫原性wt−1ペプチドおよびその使用法 |
US20160101170A1 (en) * | 2013-04-07 | 2016-04-14 | The Broad Institute Inc. | Compositions and methods for personalized neoplasia vaccines |
WO2016040682A1 (en) * | 2014-09-10 | 2016-03-17 | Genentech, Inc. | Immunogenic mutant peptide screening platform |
WO2016128376A1 (en) * | 2015-02-12 | 2016-08-18 | Biontech Ag | Predicting t cell epitopes useful for vaccination |
WO2016172722A1 (en) * | 2015-04-23 | 2016-10-27 | Nantomics, Llc | Cancer neoepitopes |
WO2016174085A1 (en) * | 2015-04-27 | 2016-11-03 | Cancer Research Technology Limited | Method for treating cancer |
WO2017011660A1 (en) * | 2015-07-14 | 2017-01-19 | Personal Genome Diagnostics, Inc. | Neoantigen analysis |
WO2017042394A1 (en) * | 2015-09-10 | 2017-03-16 | Cancer Research Technology Limited | "immune checkpoint intervention" in cancer |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2022518355A (ja) * | 2018-12-21 | 2022-03-15 | ビオンテック ユーエス インコーポレイテッド | Hlaクラスii特異的エピトープの予測およびcd4+ t細胞の特徴付けのための方法およびシステム |
JP7236543B2 (ja) | 2018-12-21 | 2023-03-09 | ビオンテック ユーエス インコーポレイテッド | Hlaクラスii特異的エピトープの予測およびcd4+ t細胞の特徴付けのための方法およびシステム |
JP7531009B2 (ja) | 2018-12-21 | 2024-08-08 | ビオンテック ユーエス インコーポレイテッド | Hlaクラスii特異的エピトープの予測およびcd4+ t細胞の特徴付けのための方法およびシステム |
Also Published As
Publication number | Publication date |
---|---|
WO2018183980A3 (en) | 2018-12-20 |
WO2018183980A2 (en) | 2018-10-04 |
TW201903411A (zh) | 2019-01-16 |
CN110799196B (zh) | 2024-02-13 |
US20210284738A1 (en) | 2021-09-16 |
TWI672503B (zh) | 2019-09-21 |
EP3600340A4 (en) | 2021-01-20 |
CN110799196A (zh) | 2020-02-14 |
US11485784B2 (en) | 2022-11-01 |
EP3600340A2 (en) | 2020-02-05 |
JP7155470B2 (ja) | 2022-10-19 |
SG11201907738UA (en) | 2019-09-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7155470B2 (ja) | 免疫原性がん特異的エピトープのためのランク付けシステム | |
RU2729116C2 (ru) | Идентификация, производство и применение неоантигенов | |
US20210113673A1 (en) | Neoantigen Identification, Manufacture, and Use | |
US20200232040A1 (en) | Neoantigens and uses thereof for treating cancer | |
IL273030B1 (en) | Neoantigen identification for T-CELL therapy | |
CN111630602A (zh) | 减少新抗原的接合表位呈递 | |
CN113711239A (zh) | 利用ii类mhc模型鉴别新抗原 | |
BR112021005702A2 (pt) | método para selecionar neoepítopos | |
WO2020221783A1 (en) | Methods for pre-selection of neoepitopes | |
CA3217623A1 (en) | Compositions and method for optimized peptide vaccines using residue optimization | |
Tang et al. | TruNeo: an integrated pipeline improves personalized true tumor neoantigen identification | |
Olsen et al. | Bioinformatics for cancer immunotherapy target discovery | |
KR20230165259A (ko) | 클론성 신항원의 동정 및 이의 용도 | |
Chuwdhury et al. | ImmuneMirror: A machine learning-based integrative pipeline and web server for neoantigen prediction | |
CN112210596A (zh) | 基于基因融合事件的肿瘤新生抗原预测方法及其应用 | |
JP2022504635A (ja) | ネオ抗原ベースの免疫療法のためのエピトープを標的化する方法およびシステム | |
CN113272419A (zh) | 制备治疗性t淋巴细胞的方法 | |
RU2826184C2 (ru) | Способ отбора неоэпитопов | |
US20240024439A1 (en) | Administration of anti-tumor vaccines | |
Spellman et al. | Enhancing the Breadth and Efficacy of Therapeutic Vaccines for Breast Cancer | |
Jaitly et al. | An integrative computational framework for personalized detection of tumor epitopes in melanoma immunotherapy | |
WO2024194208A1 (en) | Prediction of immunogenicity | |
CN117157713A (zh) | 对用于个性化癌症疫苗的新抗原进行排序 | |
Premlal | Building a Pipeline for Personalized Cancer Vaccine Design |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190930 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190930 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200507 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20200521 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20200521 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200814 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20201117 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210129 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210517 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20211109 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20220209 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220426 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20220906 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20220912 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7155470 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |